This article is more than 5 years old. Information may no longer be current.

VIDEO: ASCEND trial offers 'mixed messages' on aspirin, omega-3

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MUNICH — In this video exclusive, Jeffrey T. Kuvin, MD, FACC, provides his perspective on the ASCEND trial of aspirin and omega-3 fatty acids for primary CVD prevention in patients with diabetes.

While the trial offers valuable information, it yields “mixed messages,” Kuvin, chief of the section of cardiovascular medicine at the Heart and Vascular Center at Dartmouth-Hitchcock Medical Center and professor of medicine at Dartmouth College Geisel School of Medicine, told Cardiology Today.

In the ASCEND population, aspirin reduced vascular events but increased bleeding, while a dose of 1 g per day of omega-3 fatty acids did not reduce vascular events.

Watch the video for more.